drugset / Trial / NCT03998683

A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis

NCT03998683

Phase 3 Completed 117 enrolled Janssen-Cilag Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of guselkumab for the treatment of palmoplantar psoriasis.

Timeline

Start
2019-09-03
Primary completion
2021-03-02
Completion
2021-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody 100 mg Subcutaneous

Indications